NEWS

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734), a first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE, which accounts for 70 percent of lupus…

Commitments at the Generation Equality Forum will advance women’s economic empowerment, strengthen health and family planning, and accelerate women in leadership as women suffer disproportionately from the pandemic As part of the Generation Equality Forum convened by UN Women and co-hosted by the governments of Mexico and France, the Bill & Melinda Gates Foundation today…

Rebecca Martin, PhD, an internationally known expert in immunization, health systems strengthening and outbreak response, has been named Emory University’s new vice president for global health and director of the Emory Global Health Institute (EGHI).  Martin starts Aug. 9 and succeeds Jeffrey Koplan, MD, MPH, who founded EGHI in 2006 and was director of the…

U.S. health regulators have approved Roche’s (ROG.S) arthritis drug Actemra for emergency use to treat hospitalized COVID-19 patients, giving an extra boost to a medicine that was already allowed to be administered on compassionate grounds. The U.S. Food and Drug Administration (FDA) said on Thursday it had issued an emergency use authorization (EUA) for Actemra to treat…

The Pfizer-BioNTech >PFE.N< vaccine is highly effective against the Delta variant of COVID-19, a Pfizer official in Israel said on Thursday. First identified in India, Delta is becoming the globally dominant variant of the coronavirus, according to the World Health Organization. “The data we have today, accumulating from research we are conducting at the lab…

Osmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone paymentsAlora will acquire manufacturing operations in Marietta, Georgia in addition to legacy productsOsmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ®Osmotica will also retain arbaclofen…